Table 1 ROS1 expression and clinicopathologic parameters
From: Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma
ROS1 expression | Â | N (%) | Negative | Positive | p. |
|---|---|---|---|---|---|
| Â | 122 (62.9) | 72 (37.1) | |||
Sex (194) | Male | 149 (76.8) | 96 (64.4) | 53 (35.6) | 0.418 |
| Â | Female | 45 (23.2) | 26 (57.8) | 19 (42.2) | Â |
Age (yr) (194) | 62 [37–89] | 60.1 ± 9.0 | 61.5 ± 10.4 | 0.347 | |
Size (cm) (185) | 5.0 [0.3–26.0] | 5.5 ± 2.9 | 5.6 ± 3.9 | 0.673 | |
Operation (183) | Lobectomy | 129 (70.5) | 84 (65.1) | 45 (34.9) | 0.635 |
| Â | Segmentectomy | 54 (29.5) | 32 (59.3) | 22 (40.7) | Â |
Number (188) | Single | 169 (89.9) | 107 (63.3) | 62 (36.7) | 0.114 |
| Â | Multiple | 19 (10.1) | 14 (73.7) | 5 (26.3) | Â |
Gross type (189) | Mass forming | 133 (70.4) | 91 (68.4) | 42 (31.6) | 0.006* |
| Â | Periductal infiltrating | 10 (5.3) | 5 (50.0) | 5 (50.0) | Â |
| Â | Intraductal polypoid | 24 (12.7) | 8 (33.3) | 16 (66.7) | Â |
| Â | Mixed | 22 (11.6) | 16 (72.7) | 6 (27.3) | Â |
Extent of tumor (188) | Confined liver | 92 (48.9) | 50 (54.3) | 42 (45.7) | 0.005* |
| Â | Extrahepatic invasion | 96 (51.1) | 71 (74.0) | 25 (26.0) | Â |
pT stage (190) | Tis | 1 (0.5) | 1 (100) | 0 (0.0) | 0.226 |
| Â | T1 | 86 (45.3) | 52 (60.5) | 34 (39.5) | Â |
| Â | T2a | 39 (20.5) | 21 (53.8) | 18 (46.2) | Â |
| Â | T2b | 12 (6.3) | 9 (75.0) | 3 (25.0) | Â |
| Â | T3 | 50 (26.3) | 37 (74.0) | 13 (26.0) | Â |
| Â | T4 | 2 (1.1) | 1 (50.0) | 1 (50.0) | Â |
pN stage (106) | pN0 | 61 (57.5) | 35 (57.4) | 26 (42.6) | 0.462 |
| Â | pN1 | 45 (42.5) | 29 (64.4) | 16 (35.6) | Â |
Resection margin (177) | R0 | 151 (85.3) | 100 (66.2) | 51 (33.8) | 0.400 |
| Â | R1-2 | 26 (14.7) | 15 (57.7) | 11 (42.3) | Â |
Lymphatic invasion (187) | Absent | 117 (62.6) | 71 (60.7) | 46 (39.3) | 0.278 |
| Â | Present | 70 (37.4) | 48 (68.6) | 22 (31.4) | Â |
Vascular invasion (180) | Absent | 127 (70.6) | 81 (63.8) | 46 (36.2) | 0.595 |
| Â | Present | 53 (29.4) | 36 (67.9) | 17 (32.1) | Â |
Neural invasion (184) | Absent | 137 (74.5) | 89 (65.0) | 48 (35.0) | 0.687 |
| Â | Present | 47 (25.5) | 29 (61.7) | 18 (38.3) | Â |
Differentiation (194) | Well | 34 (17.5) | 14 (41.2) | 20 (58.8) | 0.150 |
| Â | Moderate | 112 (57.7) | 75 (67.0) | 37 (33.0) | Â |
| Â | Poor | 48 (24.7) | 33 (68.8) | 15 (31.3) | Â |
Histologic subtype (194) | Adenocarcinoma, tubular | 167 (86.1) | 111 (66.5) | 56 (33.5) | 0.009* |
| Â | Papillary or mucinous carcinoma | 15 (7.7) | 4 (26.7) | 11 (73.3) | Â |
| Â | Othersa | 12 (6.2) | 7 (58.3) | 5 (41.7) | Â |
Cell type (172) | Nonintestinal type | 137 (79.7) | 92 (67.2) | 45 (32.8) | 0.019* |
| Â | Intestinal type | 35 (20.3) | 19 (54.3) | 19 (54.3) | Â |
Progression (194) | No evidence of disease | 62 (32.0) | 34 (54.8) | 28 (45.2) | 0.024* |
| Â | Recurrence or metastasis | 119 (61.3) | 83 (69.7) | 36 (30.3) | Â |
| Â | Censored | 13 (6.7) | 5 (38.5) | 8 (61.5) | Â |
Death (194) | Alive | 60 (30.9) | 32 (53.3) | 28 (46.7) | 0.176 |
| Â | Deceased | 126 (64.9) | 85 (67.5) | 41 (32.5) | Â |
| Â | Censored | 8 (4.1) | 5 (62.5) | 3 (37.5) | Â |